Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon
the words "FDA recall" on a board

FDA announces new recall of delivery catheters after patient’s death

The recall includes specific lots of five different medical devices used to treat stroke and other neurovascular diseases.

money business cash flow dollar

Medical device company raises $87M to study new-look scaffolds for BTK PAD

R3 Vascular also announced that Christopher M. Owens, a veteran of the medical device industry, is its new president and CEO. 

Hēlo PE Thrombectomy System developed by U.S. medical device company Endovascular Engineering

Dual-action thrombectomy device could give cardiologists a new tool for treating acute PE

The new device is believed to be the first of its kind, using both aspiration and mechanical clot disruption to remove blood clots.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR linked to lower stroke risk than SAVR in patients with AS and cardiogenic shock

TAVR is also associated with a lower risk of acute kidney injury in this patient population. In-hospital mortality rates, however, are similar between the two treatment options. 

PAD patients face greater risk of death, complications after a heart attack

PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations. 

cardiologists going through the certification process

SCAI 2024 Scientific Sessions to focus on TAVR, PAD and other key trends in interventional cardiology

Interventional cardiologists from all over the world will gather for three days of educational sessions, late-breaking presentations, live cases and more. The festivities begin Thursday, May 2, in Long Beach, California. 

Cardiologist Foluso Fakorede, MD, explains the most common health disparities he sees preventing care in rural Mississippi. #PADadvocate #PAD #CLI #CLTI #Healthdisparities #HealthdisparitiesMS

Cardiologist details the many health disparities he encounters in rural Mississippi

Foluso Fakorede, MD, an interventional cardiologist with Cardiovascular Solutions of Central Mississippi, says these issues are typically overlooked in today's healthcare environment. 

Abbott's Espirit BTK Everolimus Eluting Resorbable Scaffold gained U.S. FDA approval in April 2024. It is based on the former Abbott Absorb coronary stent, but indicated for use in peripheral artery lesions below the knee (BTK).

FDA approves Abbott’s resorbable stent for BTK arteries

The bioresorbable stent, examined at length for the LIFE-BTK clinical trial, stays in place for up to three years before completely dissolving. 

Displaying 89 - 96 of 835
Design by Adaptive Theme